Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder
By F. Bymaster, J. Katner, D. Nelson, S. Hemrick-Luecke, P. Threlkeld, J. Heiligenstein, S. Morin, D. Gehlert, K. Perry. Neuropsychopharmacology, 2002
1,108 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/5a74c2125104bda514a9bb253e4ebd330e2dbdb0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
- Trevor W. Robbins
- Charles R. Yang
- A. Arnsten
- David J. Nutt
- Jeremy K. Seamans
- Michael J Frank
- Nora D. Volkow
- Torben Ott
In Psychiatry and Mental health
Citations in the corpus
- Amphetamine, past and present – a pharmacological and clinical perspective (2013, background): “…those reported for classical reuptake inhibitors such as atomoxetine or bupropion, and there is no dose-effect ceiling to amphetamine's actions (Bymaster et al., 2002; Nomikos et al., 1989, 1990; Swanson et al., 2006; see Cl Na + K + Na + /K + ATP'ase Releasing agent (amphetamine) Cytosolic…”
- The principal features and mechanisms of dopamine modulation in the prefrontal cortex. (2004, background): “Unlike striatum, a significant portion of PFC DA uptake is mediated by the norepinephrine transporter (NET) and catabolized enzymatically by COMT, more so than by MAO (Cass and Gerhardt, 1995; Wayment et al., 2001; Moron et al., 2002; Bymaster et al., 2002).”
- The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation (2009, background): “The key question remains whether the drug is exerting its beneficial effect on SSRT via cortical NE and/or DA mechanisms (Bymaster et al. 2002).”